Advertisement

Obesity, Type 2 Diabetes and Cancer

  • Rosalyn D. Ferguson
  • Derek LeRoithEmail author
Chapter
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

A large percentage of the developed world’s population is now either officially overweight or obese; meanwhile, cancer rates have been rising steadily. Cases of type 2 diabetes have also become alarmingly common. In this chapter, we discuss the epidemiological evidence which suggests that obesity, type 2 diabetes and ­cancer are linked. Possible mechanisms for obesity leading to type 2 diabetes and cancer are discussed, as well as the recent studies which potentially uncover ­therapies to treat aspects and reduce the rates of cancer associated with obesity and type 2 diabetes.

Keywords

Breast Cancer Prostate Cancer Insulin Resistance Adipose Tissue Glargine Insulin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser, 1995. 854: p. 1–452.Google Scholar
  2. Kelly, T., et al., Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond), 2008. 32(9): p. 1431–7.Google Scholar
  3. Flegal, K.M., et al., Prevalence and trends in obesity among US adults, 1999–2008. Jama. 303(3): p. 235–41.Google Scholar
  4. Wang, Y., et al., Will all Americans become overweight or obese? estimating the progression and cost of the US obesity epidemic. Obesity (Silver Spring), 2008. 16(10): p. 2323–30.Google Scholar
  5. Healthy lifestyles: Knowledge, attitudes and behavour, in Health Survey for England, NHS, Editor. 2008.Google Scholar
  6. McMichael, A.J., Food, nutrition, physical activity and cancer prevention. Authoritative report from World Cancer Research Fund provides global update. Public Health Nutr, 2008. 11(7): p. 762–3.Google Scholar
  7. Finkelstein, E.A., et al., Annual medical spending attributable to obesity: Payer- and service-specific estimates. Health Affairs, 2009. 28(5): w822–w831.Google Scholar
  8. Withrow, D. and D.A. Alter, The economic burden of obesity worldwide: a systematic review of the direct costs of obesity. Obes Rev, 2010.Google Scholar
  9. Diabetes Research and Statistics. 2007.Google Scholar
  10. Diabetes UK. What is diabetes? 2010.Google Scholar
  11. Alberti, K.G. and P.Z. Zimmet, Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med, 1998. 15(7): p. 539–53.Google Scholar
  12. Van Itallie, T.B., Health implications of overweight and obesity in the United States. Ann Intern Med, 1985. 103(6 ( Pt 2)): p. 983–8.Google Scholar
  13. Ohlson, L.O., et al., Risk factors for type 2 (non-insulin-dependent) diabetes mellitus. Thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913. Diabetologia, 1988. 31(11): p. 798–805.Google Scholar
  14. Lundgren, H., et al., Dietary habits and incidence of noninsulin-dependent diabetes mellitus in a population study of women in Gothenburg, Sweden. Am J Clin Nutr, 1989. 49(4): p. 708–12.PubMedGoogle Scholar
  15. Perry, I.J., et al., Prospective study of risk factors for development of non-insulin dependent diabetes in middle aged British men. Bmj, 1995. 310(6979): p. 560–4.PubMedGoogle Scholar
  16. Colditz, G.A., et al., Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med, 1995. 122(7): p. 481–6.PubMedGoogle Scholar
  17. Arnlov, J., et al., Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation, 2009. 121(2): p. 230–6.PubMedGoogle Scholar
  18. Willett, W.C., et al., Weight, weight change, and coronary heart disease in women. Risk within the ‘normal’ weight range. Jama, 1995. 273(6): p. 461–5.Google Scholar
  19. Rimm, E.B., et al., Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol, 1995. 141(12): p. 1117–27.PubMedGoogle Scholar
  20. Krauss, R.M., et al., Obesity: impact on cardiovascular disease. Circulation, 1998. 98(14): p. 1472–6.Google Scholar
  21. Rexrode, K.M., et al., A prospective study of body mass index, weight change, and risk of stroke in women. Jama, 1997. 277(19): p. 1539–45.PubMedGoogle Scholar
  22. Kato, I., et al., Prospective study of clinical gallbladder disease and its association with obesity, physical activity, and other factors. Dig Dis Sci, 1992. 37(5): p. 784–90.PubMedGoogle Scholar
  23. Anderson, J.J. and D.T. Felson, Factors associated with osteoarthritis of the knee in the first national Health and Nutrition Examination Survey (HANES I). Evidence for an association with overweight, race, and physical demands of work. Am J Epidemiol, 1988. 128(1): p. 179–89.Google Scholar
  24. WHO, International Agency for Research on Cancer. Nutrition and lifestyle: Opportunities for cancer prevention. 2002.Google Scholar
  25. ACS, Cancer Facts and Figures. American Cancer Society, 2010: p. 1–64.Google Scholar
  26. Vainio, H., R. Kaaks, and F. Bianchini, Weight control and physical activity in cancer prevention: international evaluation of the evidence. Eur J Cancer Prev, 2002. 11 Suppl 2: p. S94–100.Google Scholar
  27. Calle, E.E., et al., Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med, 2003. 348(17): p. 1625–38.Google Scholar
  28. Lahmann, P.H., et al., Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). Int J Cancer, 2004. 111(5): p. 762–71.PubMedGoogle Scholar
  29. Berclaz, G., et al., Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol, 2004. 15(6): p. 875–84.PubMedGoogle Scholar
  30. Dossus, L., et al., Obesity, inflammatory markers and endometrial cancer risk: a prospective case-control study. Endocr Relat Cancer 2010.Google Scholar
  31. Moore, L.L., et al., BMI and waist circumference as predictors of lifetime colon cancer risk in Framingham Study adults. Int J Obes Relat Metab Disord, 2004. 28(4): p. 559–67.PubMedGoogle Scholar
  32. Larsson, S.C. and A. Wolk, Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr, 2007. 86(3): p. 556–65.PubMedGoogle Scholar
  33. Moghaddam, A.A., M. Woodward, and R. Huxley, Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev, 2007. 16(12): p. 2533–47.PubMedGoogle Scholar
  34. Larsson, S.C., N. Orsini, and A. Wolk, Body mass index and pancreatic cancer risk: A meta-analysis of prospective studies. Int J Cancer, 2007. 120(9): p. 1993–8.PubMedGoogle Scholar
  35. Corley, D.A., A. Kubo, and W. Zhao, Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomarkers Prev, 2008. 17(2): p. 352–8.PubMedGoogle Scholar
  36. Larsson, S.C. and A. Wolk, Obesity and risk of non-Hodgkin’s lymphoma: a meta-analysis. Int J Cancer, 2007. 121(7): p. 1564–70.PubMedGoogle Scholar
  37. Birmann, B.M., et al., Body mass index, physical activity, and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev, 2007. 16(7): p. 1474–8.PubMedGoogle Scholar
  38. Kubo, A. and D.A. Corley, Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev, 2006. 15(5): p. 872–8.PubMedGoogle Scholar
  39. Welzel, T.M., et al., Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol, 2007. 5(10): p. 1221–8.PubMedGoogle Scholar
  40. Batty, G.D., et al., Obesity and overweight in relation to liver disease mortality in men: 38 year follow-up of the original Whitehall study. Int J Obes (Lond), 2008. 32(11): p. 1741–4.Google Scholar
  41. Bergstrom, A., et al., Obesity and renal cell cancer--a quantitative review. Br J Cancer, 2001. 85(7): p. 984–90.PubMedGoogle Scholar
  42. Pan, B.N., et al., [Clinical analysis of 174 cases of primary ureteral carcinoma]. Zhonghua Wai Ke Za Zhi, 2004. 42(23): p. 1447–9.PubMedGoogle Scholar
  43. Kuriyama, S., et al., Obesity and risk of cancer in Japan. Int J Cancer, 2005. 113(1): p. 148–57.PubMedGoogle Scholar
  44. Renehan, A.G., et al., Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet, 2008. 371(9612): p. 569–78.PubMedGoogle Scholar
  45. Gonzalez, C.A. and E. Riboli, Diet and cancer prevention: Contributions from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Eur J Cancer, 2010. 46(14): p. 2555–62.PubMedGoogle Scholar
  46. Ursin, G., et al., A meta-analysis of body mass index and risk of premenopausal breast cancer. Epidemiology, 1995. 6(2): p. 137–41.PubMedGoogle Scholar
  47. van den Brandt, P.A., et al., Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol, 2000. 152(6): p. 514–27.PubMedGoogle Scholar
  48. Olsen, C.M., et al., Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Eur J Cancer, 2007. 43(4): p. 690–709.PubMedGoogle Scholar
  49. Ma, J., et al., Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol, 2008. 9(11): p. 1039–47.PubMedGoogle Scholar
  50. Wallstrom, P., et al., A prospective Swedish study on body size, body composition, diabetes, and prostate cancer risk. Br J Cancer, 2009. 100(11): p. 1799–805.PubMedGoogle Scholar
  51. Khan, N., F. Afaq, and H. Mukhtar, Lifestyle as risk factor for cancer: Evidence from human studies. Cancer Lett 2010. 293(2): p. 133–43.PubMedGoogle Scholar
  52. Coughlin, S.S., et al., Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol, 2004. 159(12): p. 1160–7.PubMedGoogle Scholar
  53. Jee, S.H., et al., Fasting serum glucose level and cancer risk in Korean men and women. Jama, 2005. 293(2): p. 194–202.PubMedGoogle Scholar
  54. Inoue, M., et al., Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med, 2006. 166(17): p. 1871–7.PubMedGoogle Scholar
  55. Noto, H., et al., Substantially increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis of epidemiologic evidence in Japan. J Diabetes Complications 2010. 24(5): p. 345–53.PubMedGoogle Scholar
  56. Bruning, P.F., et al., Insulin resistance and breast-cancer risk. Int J Cancer, 1992. 52(4): p. 511–6.PubMedGoogle Scholar
  57. Weiderpass, E., et al., Risk of endometrial and breast cancer in patients with diabetes mellitus. Int J Cancer, 1997. 71(3): p. 360–3.PubMedGoogle Scholar
  58. Michels, K.B., et al., Type 2 diabetes and subsequent incidence of breast cancer in the Nurses’ Health Study. Diabetes Care, 2003. 26(6): p. 1752–8.PubMedGoogle Scholar
  59. Pisani, P., Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem, 2008. 114(1): p. 63–70.PubMedGoogle Scholar
  60. Verheus, M., et al., Serum C-peptide levels and breast cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer, 2006. 119(3): p. 659–67.PubMedGoogle Scholar
  61. Gunter, M.J., et al., Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst, 2009. 101(1): p. 48–60.PubMedGoogle Scholar
  62. Yancik, R., et al., Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. Jama, 2001. 285(7): p. 885–92.PubMedGoogle Scholar
  63. Verlato, G., et al., Mortality from site-specific malignancies in type 2 diabetic patients from Verona. Diabetes Care, 2003. 26(4): p. 1047–51.PubMedGoogle Scholar
  64. Rousseau, M.C., et al., Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. Int J Cancer, 2006. 118(8): p. 2105–9.PubMedGoogle Scholar
  65. Kuriki, K., K. Hirose, and K. Tajima, Diabetes and cancer risk for all and specific sites among Japanese men and women. Eur J Cancer Prev, 2007. 16(1): p. 83–9.PubMedGoogle Scholar
  66. Michaud, D.S., et al., Prediagnostic plasma C-peptide and pancreatic cancer risk in men and women. Cancer Epidemiol Biomarkers Prev, 2007. 16(10): p. 2101–9.PubMedGoogle Scholar
  67. Permert, J., et al., Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. N Engl J Med, 1994. 330(5): p. 313–8.PubMedGoogle Scholar
  68. Isaksson, B., et al., Impaired insulin action on phosphatidylinositol 3-kinase activity and glucose transport in skeletal muscle of pancreatic cancer patients. Pancreas, 2003. 26(2): p. 173–7.PubMedGoogle Scholar
  69. Hu, F.B., et al., Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst, 1999. 91(6): p. 542–7.PubMedGoogle Scholar
  70. Yang, Y.X., S. Hennessy, and J.D. Lewis, Type 2 diabetes mellitus and the risk of colorectal cancer. Clin Gastroenterol Hepatol, 2005. 3(6): p. 587–94.PubMedGoogle Scholar
  71. Sturmer, T., et al., Metabolic abnormalities and risk for colorectal cancer in the physicians’ health study. Cancer Epidemiol Biomarkers Prev, 2006. 15(12): p. 2391–7.PubMedGoogle Scholar
  72. Folsom, A.R., et al., Diabetes as a risk factor for death following endometrial cancer. Gynecol Oncol, 2004. 94(3): p. 740–5.PubMedGoogle Scholar
  73. Borugian, M.J., et al., Prediagnostic C-peptide and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev, 2007. 16(10): p. 2164–5.PubMedGoogle Scholar
  74. Chen, C., et al., Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer, 2005. 103(1): p. 76–84.PubMedGoogle Scholar
  75. Hubbard, J.S., et al., Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging. Urology, 2004. 63(2): p. 253–8.PubMedGoogle Scholar
  76. Bonovas, S., K. Filioussi, and A. Tsantes, Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia, 2004. 47(6): p. 1071–8.PubMedGoogle Scholar
  77. Kasper, J.S. and E. Giovannucci, A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev, 2006. 15(11): p. 2056–62.PubMedGoogle Scholar
  78. Kershaw, E.E. and J.S. Flier, Adipose tissue as an endocrine organ. J Clin Endocrinol Metab, 2004. 89(6): p. 2548–56.PubMedGoogle Scholar
  79. Grundy, S.M., Atherosclerosis imaging and the future of lipid management. Circulation, 2004. 110(23): p. 3509–11.PubMedGoogle Scholar
  80. Chang, X., et al., Solution structures of the R6 human insulin hexamer. Biochemistry, 1997. 36(31): p. 9409–22.PubMedGoogle Scholar
  81. Mosthaf, L., et al., Functionally distinct insulin receptors generated by tissue-specific alternative splicing. Embo J, 1990. 9(8): p. 2409–13.PubMedGoogle Scholar
  82. Van Obberghen, E., et al., Insulin receptor: receptor activation and signal transduction. Adv Second Messenger Phosphoprotein Res, 1993. 28: p. 195–201.PubMedGoogle Scholar
  83. Lizcano, J.M. and D.R. Alessi, The insulin signalling pathway. Curr Biol, 2002. 12(7): p. R236-8.PubMedGoogle Scholar
  84. Puigserver, P., et al., Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature, 2003. 423(6939): p. 550–5.PubMedGoogle Scholar
  85. Castan, I., et al., Mechanisms of inhibition of lipolysis by insulin, vanadate and peroxovanadate in rat adipocytes. Biochem J, 1999. 339 ( Pt 2): p. 281–9.PubMedGoogle Scholar
  86. Sciacca, L., et al., Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene, 1999. 18(15): p. 2471–9.PubMedGoogle Scholar
  87. Uhles, S., et al., Isoform-specific insulin receptor signaling involves different plasma membrane domains. J Cell Biol, 2003. 163(6): p. 1327–37.PubMedGoogle Scholar
  88. Frasca, F., et al., Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol, 1999. 19(5): p. 3278–88.PubMedGoogle Scholar
  89. Sacco, A., et al., Differential signaling activation by insulin and insulin-like growth factors I and II upon binding to insulin receptor isoform A. Endocrinology, 2009. 150(8): p. 3594–602.PubMedGoogle Scholar
  90. Galbaugh, T., et al., EGF-induced activation of Akt results in mTOR-dependent p70S6 kinase phosphorylation and inhibition of HC11 cell lactogenic differentiation. BMC Cell Biol, 2006. 7: p. 34.Google Scholar
  91. Isotani, S., et al., Immunopurified mammalian target of rapamycin phosphorylates and activates p70 S6 kinase alpha in vitro. J Biol Chem, 1999. 274(48): p. 34493–8.PubMedGoogle Scholar
  92. Flynn, A. and G. Proud, Insulin-stimulated phosphorylation of initiation factor 4E is mediated by the MAP kinase pathway. FEBS Lett, 1996. 389(2): p. 162–6.PubMedGoogle Scholar
  93. Holz, M.K., et al., mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell, 2005. 123(4): p. 569–80.PubMedGoogle Scholar
  94. Le Marchand-Brustel, Y., et al., Insulin receptor tyrosine kinase is defective in skeletal muscle of insulin-resistant obese mice. Nature, 1985. 315(6021): p. 676–9.PubMedGoogle Scholar
  95. Pessin, J.E. and A.R. Saltiel, Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest, 2000. 106(2): p. 165–9.PubMedGoogle Scholar
  96. Brassard, P., et al., Impaired plasma nonesterified fatty acid tolerance is an early defect in the natural history of type 2 diabetes. J Clin Endocrinol Metab, 2008. 93(3): p. 837–44.PubMedGoogle Scholar
  97. Boden, G., et al., FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis. Am J Physiol Endocrinol Metab, 2002. 283(1): p. E12–9.PubMedGoogle Scholar
  98. Patti, M.E., et al., Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci USA, 2003. 100(14): p. 8466–71.PubMedGoogle Scholar
  99. Peterson, L.R., et al., Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation, 2004. 109(18): p. 2191–6.PubMedGoogle Scholar
  100. Taylor, S.I. and E. Arioglu, Syndromes associated with insulin resistance and acanthosis nigricans. J Basic Clin Physiol Pharmacol, 1998. 9(2–4): p. 419–39.PubMedGoogle Scholar
  101. Stern, M.P., Strategies and prospects for finding insulin resistance genes. J Clin Invest, 2000. 106(3): p. 323–7.PubMedGoogle Scholar
  102. Gulli, G., et al., The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. Diabetes, 1992. 41(12): p. 1575–86.PubMedGoogle Scholar
  103. Kashyap, S., et al., A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes, 2003. 52(10): p. 2461–74.PubMedGoogle Scholar
  104. McGarry, J.D., What if Minkowski had been ageusic? An alternative angle on diabetes. Science, 1992. 258(5083): p. 766–70.PubMedGoogle Scholar
  105. Coppack, S.W., Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc, 2001. 60(3): p. 349–56.PubMedGoogle Scholar
  106. Hotamisligil, G.S., Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord, 2003. 27 Suppl 3: p. S53–5.Google Scholar
  107. Hotamisligil, G.S., Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes. Diabetes, 2005. 54 Suppl 2: p. S73–8.Google Scholar
  108. Levinger, I., et al., Akt, AS160, metabolic risk factors and aerobic fitness in middle-aged women. Exerc Immunol Rev 2010. 16: p. 98–104.PubMedGoogle Scholar
  109. Zhang, H.H., et al., Tumor necrosis factor-alpha stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. Diabetes, 2002. 51(10): p. 2929–35.PubMedGoogle Scholar
  110. Ruan, H., et al., Tumor necrosis factor-alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is obligatory. Diabetes, 2002. 51(5): p. 1319–36.PubMedGoogle Scholar
  111. Ye, J., Regulation of PPARgamma function by TNF-alpha. Biochem Biophys Res Commun, 2008. 374(3): p. 405–8.PubMedGoogle Scholar
  112. Fain, J.N., et al., Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology, 2004. 145(5): p. 2273–82.PubMedGoogle Scholar
  113. Vozarova, B., et al., Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res, 2001. 9(7): p. 414–7.PubMedGoogle Scholar
  114. Esposito, K., et al., Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. Jama, 2003. 289(14): p. 1799–804.PubMedGoogle Scholar
  115. Stith, R.D. and J. Luo, Endocrine and carbohydrate responses to interleukin-6 in vivo. Circ Shock, 1994. 44(4): p. 210–5.PubMedGoogle Scholar
  116. Tsigos, C. and G.P. Chrousos, Physiology of the hypothalamic-pituitary-adrenal axis in health and dysregulation in psychiatric and autoimmune disorders. Endocrinol Metab Clin North Am, 1994. 23(3): p. 451–66.PubMedGoogle Scholar
  117. Lagathu, C., et al., Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun, 2003. 311(2): p. 372–9.PubMedGoogle Scholar
  118. Rieusset, J., et al., Suppressor of cytokine signaling 3 expression and insulin resistance in skeletal muscle of obese and type 2 diabetic patients. Diabetes, 2004. 53(9): p. 2232–41.PubMedGoogle Scholar
  119. Emanuelli, B., et al., SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem, 2000. 275(21): p. 15985–91.PubMedGoogle Scholar
  120. Klover, P.J., et al., Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes, 2003. 52(11): p. 2784–9.PubMedGoogle Scholar
  121. Banerjee, R.R. and M.A. Lazar, Resistin: molecular history and prognosis. J Mol Med, 2003. 81(4): p. 218–26.PubMedGoogle Scholar
  122. Steppan, C.M., et al., The hormone resistin links obesity to diabetes. Nature, 2001. 409(6818): p. 307–12.PubMedGoogle Scholar
  123. Li, J., et al., Gene expression profile of rat adipose tissue at the onset of high-fat-diet obesity. Am J Physiol Endocrinol Metab, 2002. 282(6): p. E1334–41.PubMedGoogle Scholar
  124. Juan, C.C., et al., Suppressed gene expression of adipocyte resistin in an insulin-resistant rat model probably by elevated free fatty acids. Biochem Biophys Res Commun, 2001. 289(5): p. 1328–33.PubMedGoogle Scholar
  125. Le Lay, S., et al., Decreased resistin expression in mice with different sensitivities to a high-fat diet. Biochem Biophys Res Commun, 2001. 289(2): p. 564–7.PubMedGoogle Scholar
  126. Haugen, F., et al., Inhibition by insulin of resistin gene expression in 3T3-L1 adipocytes. FEBS Lett, 2001. 507(1): p. 105–8.PubMedGoogle Scholar
  127. Owecki, M., et al., Serum Resistin Concentrations are Higher in Human Obesity but Independent from Insulin Resistance. Exp Clin Endocrinol Diabetes, 2010.Google Scholar
  128. Bjorbaek, C. and B.B. Kahn, Leptin signaling in the central nervous system and the periphery. Recent Prog Horm Res, 2004. 59: p. 305–31.PubMedGoogle Scholar
  129. Ahima, R.S. and J.S. Flier, Leptin. Annu Rev Physiol, 2000. 62: p. 413–37.PubMedGoogle Scholar
  130. Farooqi, I.S. and S. O’Rahilly, Monogenic human obesity syndromes. Recent Prog Horm Res, 2004. 59: p. 409–24.PubMedGoogle Scholar
  131. Zelissen, P.M., et al., Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial. Diabetes Obes Metab, 2005. 7(6): p. 755–61.PubMedGoogle Scholar
  132. Hedbacker, K., et al., Antidiabetic effects of IGFBP2, a leptin-regulated gene. Cell Metab, 2010. 11(1): p. 11–22.PubMedGoogle Scholar
  133. Maeda, R., et al., [Genetic analysis of left-right asymmetry in Drosophila melanogaster]. Seikagaku, 2007. 79(12): p. 1131–4.PubMedGoogle Scholar
  134. Scherer, P.E., et al., A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem, 1995. 270(45): p. 26746–9.PubMedGoogle Scholar
  135. Nakano, Y., et al., Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem, 1996. 120(4): p. 803–12.PubMedGoogle Scholar
  136. Hu, E., P. Liang, and B.M. Spiegelman, AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem, 1996. 271(18): p. 10697–703.PubMedGoogle Scholar
  137. Chandran, M., et al., Adiponectin: more than just another fat cell hormone? Diabetes Care, 2003. 26(8): p. 2442–50.PubMedGoogle Scholar
  138. Yamauchi, T., et al., Dual roles of adiponectin/Acrp30 in vivo as an anti-diabetic and anti-atherogenic adipokine. Curr Drug Targets Immune Endocr Metabol Disord, 2003. 3(4): p. 243–54.PubMedGoogle Scholar
  139. Diez, J.J. and P. Iglesias, The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol, 2003. 148(3): p. 293–300.PubMedGoogle Scholar
  140. Yamamoto, Y., et al., Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. J Clin Endocrinol Metab, 2004. 89(1): p. 87–90.PubMedGoogle Scholar
  141. Nakashima, R., et al., Decreased total and high molecular weight adiponectin are independent risk factors for the development of type 2 diabetes in Japanese-Americans. J Clin Endocrinol Metab, 2006. 91(10): p. 3873–7.PubMedGoogle Scholar
  142. Kinlaw, W.B. and B. Marsh, Adiponectin and HIV-lipodystrophy: taking HAART. Endocrinology, 2004. 145(2): p. 484–6.PubMedGoogle Scholar
  143. Matsuzawa, Y., et al., Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol, 2004. 24(1): p. 29–33.PubMedGoogle Scholar
  144. Kadowaki, T. and T. Yamauchi, Adiponectin and adiponectin receptors. Endocr Rev, 2005. 26(3): p. 439–51.PubMedGoogle Scholar
  145. Yamaguchi, N., et al., Adiponectin inhibits Toll-like receptor family-induced signaling. FEBS Lett, 2005. 579(30): p. 6821–6.PubMedGoogle Scholar
  146. Mullen, K.L., et al., Adiponectin resistance precedes the accumulation of skeletal muscle lipids and insulin resistance in high-fat-fed rats. Am J Physiol Regul Integr Comp Physiol, 2009. 296(2): p. R243–51.PubMedGoogle Scholar
  147. Serrano, R., et al., Differential gene expression of insulin receptor isoforms A and B and insulin receptor substrates 1, 2 and 3 in rat tissues: modulation by aging and differentiation in rat adipose tissue. J Mol Endocrinol, 2005. 34(1): p. 153–61.PubMedGoogle Scholar
  148. Osborne, C.K., et al., Correlation among insulin binding, degradation, and biological activity in human breast cancer cells in long-term tissue culture. Cancer Res, 1978. 38(1): p. 94–102.PubMedGoogle Scholar
  149. Papa, V., et al., Elevated insulin receptor content in human breast cancer. J Clin Invest, 1990. 86(5): p. 1503–10.PubMedGoogle Scholar
  150. Milazzo, G., et al., Insulin receptor expression and function in human breast cancer cell lines. Cancer Res, 1992. 52(14): p. 3924–30.PubMedGoogle Scholar
  151. Giorgino, F., et al., Overexpression of insulin receptors in fibroblast and ovary cells induces a ligand-mediated transformed phenotype. Mol Endocrinol, 1991. 5(3): p. 452–9.PubMedGoogle Scholar
  152. Frittitta, L., et al., Insulin receptor overexpression in 184B5 human mammary epithelial cells induces a ligand-dependent transformed phenotype. J Cell Biochem, 1995. 57(4): p. 666–9.PubMedGoogle Scholar
  153. Mathieu, M.C., et al., Insulin receptor expression and clinical outcome in node-negative breast cancer. Proc Assoc Am Physicians, 1997. 109(6): p. 565–71.PubMedGoogle Scholar
  154. Law, J.H., et al., Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res, 2008. 68(24): p. 10238–46.PubMedGoogle Scholar
  155. Nagamani, M. and C.A. Stuart, Specific binding and growth-promoting activity of insulin in endometrial cancer cells in culture. Am J Obstet Gynecol, 1998. 179(1): p. 6–12.PubMedGoogle Scholar
  156. Kalli, K.R., et al., Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling. Endocrinology, 2002. 143(9): p. 3259–67.PubMedGoogle Scholar
  157. Beck, E.P., et al., Identification of insulin and insulin-like growth factor I (IGF I) receptors in ovarian cancer tissue. Gynecol Oncol, 1994. 53(2): p. 196–201.PubMedGoogle Scholar
  158. Wahner Hendrickson, A.E., et al., Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro. Cancer Res, 2009. 69(19): p. 7635–43.Google Scholar
  159. Koenuma, M., T. Yamori, and T. Tsuruo, Insulin and insulin-like growth factor 1 stimulate proliferation of metastatic variants of colon carcinoma 26. Jpn J Cancer Res, 1989. 80(1): p. 51–8.PubMedGoogle Scholar
  160. Cox, M.E., et al., Insulin receptor expression by human prostate cancers. Prostate, 2009. 69(1): p. 33–40.PubMedGoogle Scholar
  161. Vella, V., et al., The IGF system in thyroid cancer: new concepts. Mol Pathol, 2001. 54(3): p. 121–4.PubMedGoogle Scholar
  162. Fernandez, A.M., et al., Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev, 2001. 15(15): p. 1926–34.PubMedGoogle Scholar
  163. Novosyadlyy, R., et al., Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res, 2010. 70(2): p. 741–51.PubMedGoogle Scholar
  164. Fierz, Y., et al., Insulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression. Diabetes, 2010. 59(3): p. 686–93.PubMedGoogle Scholar
  165. Tran, T.T., et al., Direct measure of insulin sensitivity with the hyperinsulinemic-euglycemic clamp and surrogate measures of insulin sensitivity with the oral glucose tolerance test: correlations with aberrant crypt foci promotion in rats. Cancer Epidemiol Biomarkers Prev, 2003. 12(1): p. 47–56.PubMedGoogle Scholar
  166. Yakar, S., et al., Increased tumor growth in mice with diet-induced obesity: impact of ovarian hormones. Endocrinology, 2006. 147(12): p. 5826–34.PubMedGoogle Scholar
  167. Venkateswaran, V., et al., Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst, 2007. 99(23): p. 1793–800.PubMedGoogle Scholar
  168. Bahr, C. and B. Groner, The insulin like growth factor-1 receptor (IGF-1R) as a drug target: novel approaches to cancer therapy. Growth Horm IGF Res, 2004. 14(4): p. 287–95.PubMedGoogle Scholar
  169. Baxter, R.C., J.M. Bryson, and J.R. Turtle, Somatogenic receptors of rat liver: regulation by ­insulin. Endocrinology, 1980. 107(4): p. 1176–81.PubMedGoogle Scholar
  170. Wang, H.S. and T.H. Wang, Polycystic ovary syndrome (PCOS), insulin resistance and insulin-like growth factors (IGfs)/IGF-binding proteins (IGFBPs). Chang Gung Med J, 2003. 26(8): p. 540–53.PubMedGoogle Scholar
  171. Nestler, J.E., et al., A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab, 1991. 72(1): p. 83–9.PubMedGoogle Scholar
  172. van Agthoven, T., et al., Expression of estrogen, progesterone and epidermal growth factor receptors in primary and metastatic breast cancer. Int J Cancer, 1995. 63(6): p. 790–3.PubMedGoogle Scholar
  173. Soos, M.A., et al., Receptors for insulin and insulin-like growth factor-I can form hybrid dimers. Characterisation of hybrid receptors in transfected cells. Biochem J, 1990. 270(2): p. 383–90.Google Scholar
  174. Pandini, G., et al., Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res, 1999. 5(7): p. 1935–44.PubMedGoogle Scholar
  175. Pandini, G., et al., Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem, 2002. 277(42): p. 39684–95.PubMedGoogle Scholar
  176. Pandini, G., et al., Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur J Cancer, 2007. 43(8): p. 1318–27.PubMedGoogle Scholar
  177. Buck, E., et al., Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther, 2010. 9(10): p. 2652–64.PubMedGoogle Scholar
  178. Yudkin, J.S., B. Richter, and E.A. Gale, Intensive treatment of hyperglycaemia: what are the objectives? Lancet, 2010. 376(9751): p. 1462–3.PubMedGoogle Scholar
  179. Stattin, P., et al., Prospective study of hyperglycemia and cancer risk. Diabetes Care, 2007. 30(3): p. 561–7.PubMedGoogle Scholar
  180. Bowker, S.L. and J.A. Johnson, Prospective study of hyperglycemia and cancer risk: response to Stattin et al. Diabetes Care, 2007. 30(7): p. e77; author reply e78.Google Scholar
  181. Levine, W., et al., Post-load plasma glucose and cancer mortality in middle-aged men and women. 12-year follow-up findings of the Chicago Heart Association Detection Project in Industry. Am J Epidemiol, 1990. 131(2): p. 254–62.Google Scholar
  182. Smith, G.D., et al., Post-challenge glucose concentration, impaired glucose tolerance, diabetes, and cancer mortality in men. Am J Epidemiol, 1992. 136(9): p. 1110–4.PubMedGoogle Scholar
  183. Tulinius, H., et al., Risk factors for malignant diseases: a cohort study on a population of 22,946 Icelanders. Cancer Epidemiol Biomarkers Prev, 1997. 6(11): p. 863–73.PubMedGoogle Scholar
  184. Saydah, S.H., et al., Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol, 2003. 157(12): p. 1092–100.PubMedGoogle Scholar
  185. Rapp, K., et al., Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia, 2006. 49(5): p. 945–52.PubMedGoogle Scholar
  186. Yamagata, H., et al., Impact of fasting plasma glucose levels on gastric cancer incidence in a general Japanese population: the Hisayama study. Diabetes Care, 2005. 28(4): p. 789–94.PubMedGoogle Scholar
  187. Shikany, J.M., et al., Association of glycemic load with cardiovascular disease risk factors: the Women’s Health Initiative Observational Study. Nutrition, 2010. 26(6): p. 641–7.PubMedGoogle Scholar
  188. Kodama, Y., et al., Enhanced tumorigenesis of forestomach tumors induced by N-Methyl-N’-nitro-N-nitrosoguanidine in rats with hypoinsulinemic diabetes. Cancer Sci, 2010. 101(7): p. 1604–9.PubMedGoogle Scholar
  189. Liu, H., Q. Ma, and J. Li, High glucose promotes cell proliferation and enhances GDNF and RET expression in pancreatic cancer cells. Mol Cell Biochem 2010.Google Scholar
  190. Warburg, O., On the origin of cancer cells. Science, 1956. 123(3191): p. 309–14.PubMedGoogle Scholar
  191. Gatenby, R.A. and R.J. Gillies, Why do cancers have high aerobic glycolysis? Nat Rev Cancer, 2004. 4(11): p. 891–9.PubMedGoogle Scholar
  192. Bui, T. and C.B. Thompson, Cancer’s sweet tooth. Cancer Cell, 2006. 9(6): p. 419–20.PubMedGoogle Scholar
  193. Kunkel, M., et al., Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer, 2003. 97(4): p. 1015–24.PubMedGoogle Scholar
  194. Younes, M., et al., Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res, 1996. 56(5): p. 1164–7.PubMedGoogle Scholar
  195. Zhang, F. and R.L. Aft, Chemosensitizing and cytotoxic effects of 2-deoxy-D-glucose on breast cancer cells. J Cancer Res Ther, 2009. 5 Suppl 1: p. S41–3.Google Scholar
  196. Melstrom, L.G., et al., Adenocarcinoma of the gastroesophageal junction after bariatric surgery. Am J Surg, 2008. 196(1): p. 135–8.PubMedGoogle Scholar
  197. Jurica, M.S., et al., The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate. Structure, 1998. 6(2): p. 195–210.PubMedGoogle Scholar
  198. Christofk, H.R., et al., The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature, 2008. 452(7184): p. 230–3.PubMedGoogle Scholar
  199. David, C.J., et al., HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature, 2009. 463(7279): p. 364–8.PubMedGoogle Scholar
  200. Reaven, G.M., Syndrome X: is one enough? Am Heart J, 1994. 127(5): p. 1439–42.PubMedGoogle Scholar
  201. Parks, E.J., Effect of dietary carbohydrate on triglyceride metabolism in humans. J Nutr, 2001. 131(10): p. 2772S–2774S.PubMedGoogle Scholar
  202. Miettinen, T.A. and H. Gylling, Cholesterol absorption efficiency and sterol metabolism in obesity. Atherosclerosis, 2000. 153(1): p. 241–8.PubMedGoogle Scholar
  203. Simonen, P.P., H.K. Gylling, and T.A. Miettinen, Diabetes contributes to cholesterol metabolism regardless of obesity. Diabetes Care, 2002. 25(9): p. 1511–5.PubMedGoogle Scholar
  204. Pihlajamaki, J., et al., Insulin resistance is associated with increased cholesterol synthesis and decreased cholesterol absorption in normoglycemic men. J Lipid Res, 2004. 45(3): p. 507–12.PubMedGoogle Scholar
  205. Mondul, A.M., et al., Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes Control, 2010. 21(1): p. 61–8.PubMedGoogle Scholar
  206. Yamada, K., et al., Relation of serum total cholesterol, serum triglycerides and fasting plasma glucose to colorectal carcinoma in situ. Int J Epidemiol, 1998. 27(5): p. 794–8.PubMedGoogle Scholar
  207. Sako, A., et al., Hyperlipidemia is a risk factor for lymphatic metastasis in superficial esophageal carcinoma. Cancer Lett, 2004. 208(1): p. 43–9.PubMedGoogle Scholar
  208. Tseng, T.H., et al., Promotion of colon carcinogenesis through increasing lipid peroxidation induced in rats by a high cholesterol diet. Cancer Lett, 1996. 100(1–2): p. 81–7.PubMedGoogle Scholar
  209. Blais, L., A. Desgagne, and J. LeLorier, 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med, 2000. 160(15): p. 2363–8.PubMedGoogle Scholar
  210. Coogan, P.F., et al., Statin use and the risk of breast and prostate cancer. Epidemiology, 2002. 13(3): p. 262–7.PubMedGoogle Scholar
  211. Graaf, M.R., et al., Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev, 2004. 30(7): p. 609–41.PubMedGoogle Scholar
  212. Kaye, J.A., et al., Statin use, hyperlipidaemia, and the risk of breast cancer. Br J Cancer, 2002. 86(9): p. 1436–9.PubMedGoogle Scholar
  213. Olsen, J.H., et al., Lipid-lowering medication and risk of cancer. J Clin Epidemiol, 1999. 52(2): p. 167–9.PubMedGoogle Scholar
  214. Shannon, J., et al., Statins and prostate cancer risk: a case-control study. Am J Epidemiol, 2005. 162(4): p. 318–25.PubMedGoogle Scholar
  215. Platz, E.A., et al., Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst, 2006. 98(24): p. 1819–25.PubMedGoogle Scholar
  216. Feldman, B.J. and D. Feldman, The development of androgen-independent prostate cancer. Nat Rev Cancer, 2001. 1(1): p. 34–45.PubMedGoogle Scholar
  217. Goldenberg, S.L., et al., Clinical Experience with Intermittent Androgen Suppression in Prostate Cancer: Minimum of 3 Years’ Follow-Up. Mol Urol, 1999. 3(3): p. 287–292.PubMedGoogle Scholar
  218. Leon, C.G., et al., Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate, 2010. 70(4): p. 390–400.PubMedGoogle Scholar
  219. Brown, M.S. and J.L. Goldstein, A receptor-mediated pathway for cholesterol homeostasis. Science, 1986. 232(4746): p. 34–47.PubMedGoogle Scholar
  220. Calvo, D., et al., CLA-1 is an 85-kD plasma membrane glycoprotein that acts as a high-affinity receptor for both native (HDL, LDL, and VLDL) and modified (OxLDL and AcLDL) lipoproteins. Arterioscler Thromb Vasc Biol, 1997. 17(11): p. 2341–9.PubMedGoogle Scholar
  221. Nieland, T.J., et al., Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BI. Proc Natl Acad Sci U S A, 2002. 99(24): p. 15422–7.PubMedGoogle Scholar
  222. Cao, W.M., et al., A mutant high-density lipoprotein receptor inhibits proliferation of human breast cancer cells. Cancer Res, 2004. 64(4): p. 1515–21.PubMedGoogle Scholar
  223. Adam, R.M., et al., Cholesterol sensitivity of endogenous and myristoylated Akt. Cancer Res, 2007. 67(13): p. 6238–46.PubMedGoogle Scholar
  224. Mollinedo, F., et al., Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X(L). Cancer Res, 1997. 57(7): p. 1320–8.PubMedGoogle Scholar
  225. Gajate, C. and F. Mollinedo, Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood, 2007. 109(2): p. 711–9.PubMedGoogle Scholar
  226. Gajate, C., et al., Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis. J Exp Med, 2004. 200(3): p. 353–65.PubMedGoogle Scholar
  227. Mollinedo, F. and C. Gajate, Lipid rafts and clusters of apoptotic signaling molecule-enriched rafts in cancer therapy. Future Oncol, 2010. 6(5): p. 811–21.PubMedGoogle Scholar
  228. Kang, J.H., B.Y. Yu, and D.S. Youn, Relationship of serum adiponectin and resistin levels with breast cancer risk. J Korean Med Sci, 2007. 22(1): p. 117–21.PubMedGoogle Scholar
  229. Sun, C.A., et al., Adipocytokine resistin and breast cancer risk. Breast Cancer Res Treat, 2010. 123(3): p. 869–76.PubMedGoogle Scholar
  230. Kim, H.J., et al., Expression of resistin in the prostate and its stimulatory effect on prostate cancer cell proliferation. BJU Int, 2010.Google Scholar
  231. Nakajima, S., et al., Spectra of functional gastrointestinal disorders diagnosed by Rome III integrative questionnaire in a Japanese outpatient office and the impact of overlapping. J Gastroenterol Hepatol, 2010. 25 Suppl 1: p. S138–43.Google Scholar
  232. Nakajima, T.E., et al., Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol, 2009. 44(7): p. 685–90.PubMedGoogle Scholar
  233. Wagsater, D., et al., Resistin in human colorectal cancer: increased expression independently of resistin promoter -420C > G genotype. Cancer Invest, 2008. 26(10): p. 1008–14.PubMedGoogle Scholar
  234. Somasundar, P., et al., Differential effects of leptin on cancer in vitro. J Surg Res, 2003. 113(1): p. 50–5.PubMedGoogle Scholar
  235. Ray, A., K.J. Nkhata, and M.P. Cleary, Effects of leptin on human breast cancer cell lines in relationship to estrogen receptor and HER2 status. Int J Oncol, 2007. 30(6): p. 1499–509.PubMedGoogle Scholar
  236. Hu, X., et al., Leptin--a growth factor in normal and malignant breast cells and for normal mammary gland development. J Natl Cancer Inst, 2002. 94(22): p. 1704–11.PubMedGoogle Scholar
  237. Dieudonne, M.N., et al., Leptin mediates a proliferative response in human MCF7 breast cancer cells. Biochem Biophys Res Commun, 2002. 293(1): p. 622–8.PubMedGoogle Scholar
  238. Mauro, L., et al., Evidences that leptin up-regulates E-cadherin expression in breast cancer: effects on tumor growth and progression. Cancer Res, 2007. 67(7): p. 3412–21.PubMedGoogle Scholar
  239. Cleary, M.P., et al., Diet-induced obesity and mammary tumor development in MMTV-neu female mice. Nutr Cancer, 2004. 50(2): p. 174–80.PubMedGoogle Scholar
  240. Caldefie-Chezet, F., et al., Troglitazone reduces leptinemia during experimental dexamethasone-induced stress. Horm Metab Res, 2005. 37(3): p. 164–71.PubMedGoogle Scholar
  241. Jarde, T., et al., Leptin and leptin receptor involvement in cancer development: a study on human primary breast carcinoma. Oncol Rep, 2008. 19(4): p. 905–11.PubMedGoogle Scholar
  242. Karaduman, M., et al., Tissue leptin levels in patients with breast cancer. J BUON, 2010. 15(2): p. 369–72.PubMedGoogle Scholar
  243. Surmacz, E., Obesity hormone leptin: a new target in breast cancer? Breast Cancer Res, 2007. 9(1): p. 301.PubMedGoogle Scholar
  244. Melen-Mucha, G., K. Winczyk, and M. Pawlikowski, Somatostatin analogue octreotide and melatonin inhibit bromodeoxyuridine incorporation into cell nuclei and enhance apoptosis in the transplantable murine colon 38 cancer. Anticancer Res, 1998. 18(5A): p. 3615–9.Google Scholar
  245. Ogunwobi, O.O. and I.L. Beales, Glycine-extended gastrin stimulates proliferation and inhibits apoptosis in colon cancer cells via cyclo-oxygenase-independent pathways. Regul Pept, 2006. 134(1): p. 1–8.PubMedGoogle Scholar
  246. Slattery, M.L., et al., Leptin and leptin receptor genotypes and colon cancer: gene-gene and gene-lifestyle interactions. Int J Cancer, 2008. 122(7): p. 1611–7.PubMedGoogle Scholar
  247. Gade-Andavolu, R., et al., Molecular interactions of leptin and prostate cancer. Cancer J, 2006. 12(3): p. 201–6.PubMedGoogle Scholar
  248. Mistry, T., et al., Leptin and adiponectin interact in the regulation of prostate cancer cell growth via modulation of p53 and bcl-2 expression. BJU Int, 2008. 101(10): p. 1317–22.PubMedGoogle Scholar
  249. Huang, C.Y., et al., Leptin increases motility and integrin up-regulation in human prostate cancer cells. J Cell Physiol, 2010.Google Scholar
  250. Singh, S.K., et al., Serum leptin: A marker of prostate cancer irrespective of obesity. Cancer Biomark, 2010. 7(1): p. 11–5.PubMedGoogle Scholar
  251. Nkhata, K.J., et al., Effects of adiponectin and leptin co-treatment on human breast cancer cell growth. Oncol Rep, 2009. 21(6): p. 1611–9.PubMedGoogle Scholar
  252. Chen, X. and Y. Wang, Adiponectin and breast cancer. Med Oncol, 2010.Google Scholar
  253. Jarde, T., et al., Molecular mechanisms of leptin and adiponectin in breast cancer. Eur J Cancer, 2010.Google Scholar
  254. Lopez Fontana, C.M., et al., [Influence of leptin and adiponectin on prostate cancer]. Arch Esp Urol, 2009. 62(2): p. 103–8.Google Scholar
  255. Kim, A.Y., et al., Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. Mol Endocrinol, 2010. 24(7): p. 1441–52.PubMedGoogle Scholar
  256. Mocellin, S. and D. Nitti, TNF and cancer: the two sides of the coin. Front Biosci, 2008. 13: p. 2774–83.PubMedGoogle Scholar
  257. Bertazza, L. and S. Mocellin, The dual role of tumor necrosis factor (TNF) in cancer biology. Curr Med Chem, 2010. 17(29): p. 3337–3352.PubMedGoogle Scholar
  258. Alcover, J., et al., Prognostic value of IL-6 in localized prostatic cancer. Anticancer Res, 2010. 30(10): p. 4369–72.PubMedGoogle Scholar
  259. Asgeirsson, K.S., et al., The effects of IL-6 on cell adhesion and e-cadherin expression in breast cancer. Cytokine, 1998. 10(9): p. 720–8.PubMedGoogle Scholar
  260. Ashizawa, T., et al., Study of interleukin-6 in the spread of colorectal cancer: the diagnostic ­significance of IL-6. Acta Med Okayama, 2006. 60(6): p. 325–30.PubMedGoogle Scholar
  261. Ali, S. and R.C. Coombes, Estrogen receptor alpha in human breast cancer: occurrence and ­significance. J Mammary Gland Biol Neoplasia, 2000. 5(3): p. 271–81.PubMedGoogle Scholar
  262. Gaforio, J.J., et al., Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis. Int J Cancer, 2003. 107(6): p. 984–90.PubMedGoogle Scholar
  263. Kirilovas, D., et al., Conversion of circulating estrone sulfate to 17beta-estradiol by ovarian tumor tissue: a possible mechanism behind elevated circulating concentrations of 17beta-estradiol in postmenopausal women with ovarian tumors. Gynecol Endocrinol, 2007. 23(1): p. 25–8.PubMedGoogle Scholar
  264. Means, G.D., et al., Structural analysis of the gene encoding human aromatase cytochrome P-450, the enzyme responsible for estrogen biosynthesis. J Biol Chem, 1989. 264(32): p. 19385–91.PubMedGoogle Scholar
  265. Dos Santos, E., et al., Effects of 17beta-estradiol on preadipocyte proliferation in human adipose tissue: Involvement of IGF1-R signaling. Horm Metab Res, 2010. 42(7): p. 514–20.PubMedGoogle Scholar
  266. Borkowski, A., et al., Estrone to estradiol conversion by blood mononuclear cells in normal ­subjects and in patients with mammary and nonmammary carcinomas. Cancer Res, 1978. 38(7): p. 2174–9.PubMedGoogle Scholar
  267. Hankinson, S.E., et al., Plasma sex steroid hormone levels and risk of breast cancer in ­postmenopausal women. J Natl Cancer Inst, 1998. 90(17): p. 1292–9.PubMedGoogle Scholar
  268. McTiernan, A., et al., Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women’s Health Initiative Cohort Study. JAMA, 2003. 290(10): p. 1331–6.PubMedGoogle Scholar
  269. Castracane, V.D., et al., Interrelationships of serum estradiol, estrone, and estrone sulfate, adiposity, biochemical bone markers, and leptin in post-menopausal women. Maturitas, 2006. 53(2): p. 217–25.PubMedGoogle Scholar
  270. McTiernan, A., et al., Relation of BMI and physical activity to sex hormones in postmenopausal women. Obesity (Silver Spring), 2006. 14(9): p. 1662–77.Google Scholar
  271. Rinaldi, S., et al., IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer, 2006. 13(2): p. 593–605.PubMedGoogle Scholar
  272. Rose, D.P. and L. Vona-Davis, Interaction between menopausal status and obesity in affecting breast cancer risk. Maturitas, 2010. 66(1): p. 33–8.PubMedGoogle Scholar
  273. Purohit, A. and M.J. Reed, Regulation of estrogen synthesis in postmenopausal women. Steroids, 2002. 67(12): p. 979–83.PubMedGoogle Scholar
  274. Zhao, Y., C.R. Mendelson, and E.R. Simpson, Characterization of the sequences of the human CYP19 (aromatase) gene that mediate regulation by glucocorticoids in adipose stromal cells and fetal hepatocytes. Mol Endocrinol, 1995. 9(3): p. 340–9.PubMedGoogle Scholar
  275. Mouridsen, H.T., et al., Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. Expert Rev Anticancer Ther, 2010.Google Scholar
  276. Bowker, S.L., et al., Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Farooki and Schneider. Diabetes Care, 2006. 29(8): p. 1990–1.PubMedGoogle Scholar
  277. Currie, C.J., The longest ever randomised controlled trial of insulin glargine: study design and HbA(1c) findings. Diabetologia, 2009. 52(10): p. 2234–5; author reply 2236–9.Google Scholar
  278. Yang, Y.X., S. Hennessy, and J.D. Lewis, Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology, 2004. 127(4): p. 1044–50.PubMedGoogle Scholar
  279. Stammberger, I., et al., Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol, 2002. 21(3): p. 171–9.PubMedGoogle Scholar
  280. Kurtzhals, P., et al., Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes, 2000. 49(6): p. 999–1005.PubMedGoogle Scholar
  281. Mayer, D., A. Shukla, and H. Enzmann, Proliferative effects of insulin analogues on mammary epithelial cells. Arch Physiol Biochem, 2008. 114(1): p. 38–44.PubMedGoogle Scholar
  282. Weinstein, D., et al., Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev, 2009. 25(1): p. 41–9.PubMedGoogle Scholar
  283. Hemkens, L.G., et al., Insulin glargine and cancer. Lancet, 2009. 374(9703): p. 1743–4; author reply 1744.Google Scholar
  284. de Miguel-Yanes, J.M. and J.B. Meigs, When “flawed” translates into “flood”: the unproven ­association between cancer incidence and glargine insulin therapy. Oncologist, 2009. 14(12): p. 1175–7.PubMedGoogle Scholar
  285. Colhoun, H.M., Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia, 2009. 52(9): p. 1755–65.PubMedGoogle Scholar
  286. Jonasson, J.M., et al., Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia, 2009. 52(9): p. 1745–54.PubMedGoogle Scholar
  287. Correia, S., et al., Metformin protects the brain against the oxidative imbalance promoted by type 2 diabetes. Med Chem, 2008. 4(4): p. 358–64.PubMedGoogle Scholar
  288. Cazzaniga, M., et al., Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev, 2009. 18(3): p. 701–5.PubMedGoogle Scholar
  289. Zakikhani, M., et al., Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res, 2006. 66(21): p. 10269–73.PubMedGoogle Scholar
  290. Zakikhani, M., et al., The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila), 2008. 1(5): p. 369–75.Google Scholar
  291. Hirsch, I.B., Metformin added to insulin therapy in poorly controlled type 2 diabetes. Diabetes Care, 1999. 22(5): p. 854.PubMedGoogle Scholar
  292. Ben Sahra, I., et al., The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene, 2008. 27(25): p. 3576–86.Google Scholar
  293. Anisimov, V.N., et al., Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol, 2005. 40(8–9): p. 685–93.PubMedGoogle Scholar
  294. Buzzai, M., et al., Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res, 2007. 67(14): p. 6745–52.PubMedGoogle Scholar
  295. Ben Sahra, I., et al., Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther, 2010. 9(5): p. 1092–9.Google Scholar
  296. Evans, J.M., et al., Metformin and reduced risk of cancer in diabetic patients. BMJ, 2005. 330(7503): p. 1304–5.PubMedGoogle Scholar
  297. Goodwin, S.S., et al., Breast cancer screening in Rockland County, New York: a survey of attitudes and behaviors. Ethn Dis, 2006. 16(2): p. 428–34.PubMedGoogle Scholar
  298. Goodwin, P.J., et al., Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer, 2008. 8(6): p. 501–5.PubMedGoogle Scholar
  299. Libby, G., et al., New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care, 2009. 32(9): p. 1620–5.PubMedGoogle Scholar
  300. Landman, G.W., et al., Increased cancer mortality in type 2 diabetes (ZODIAC-3). Anticancer Res, 2008. 28(2B): p. 1373–5.Google Scholar
  301. Jiralerspong, S., et al., Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol, 2009. 27(20): p. 3297–302.PubMedGoogle Scholar
  302. Bodmer, M., et al., Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care, 2010. 33(6): p. 1304–8.PubMedGoogle Scholar
  303. Liu, B., et al., Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle, 2009. 8(13): p. 2031–40.PubMedGoogle Scholar
  304. Vazquez-Martin, A., et al., The anti-diabetic drug metformin suppresses self-renewal and ­proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res Treat, 2010.Google Scholar
  305. Gupta, R., P. Vyas, and T. Enver, Molecular targeting of cancer stem cells. Cell Stem Cell, 2009. 5(2): p. 125–6.PubMedGoogle Scholar
  306. Nguyen, N.P., et al., Molecular biology of breast cancer stem cells: potential clinical applications. Cancer Treat Rev, 2010. 36(6): p. 485–91.PubMedGoogle Scholar
  307. Oliveras-Ferraros, C., et al., Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin). Biochem Biophys Res Commun, 2010. 397(1): p. 27–33.PubMedGoogle Scholar
  308. Gonzalez-Angulo, A.M. and F. Meric-Bernstam, Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res, 2010. 16(6): p. 1695–700.PubMedGoogle Scholar
  309. Wysocki, P.J. and B. Wierusz-Wysocka, Obesity, hyperinsulinemia and breast cancer: novel ­targets and a novel role for metformin. Expert Rev Mol Diagn, 2010. 10(4): p. 509–19.PubMedGoogle Scholar
  310. Sarraf, P., et al., Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med, 1998. 4(9): p. 1046–52.PubMedGoogle Scholar
  311. Mueller, E., et al., Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA, 2000. 97(20): p. 10990–5.PubMedGoogle Scholar
  312. Elstner, E., et al., Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA, 1998. 95(15): p. 8806–11.PubMedGoogle Scholar
  313. Saez, E., et al., PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev, 2004. 18(5): p. 528–40.PubMedGoogle Scholar
  314. Lefebvre, A.M., et al., Activation of the peroxisome proliferator-activated receptor gamma ­promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med, 1998. 4(9): p. 1053–7.PubMedGoogle Scholar
  315. Dormandy, J.A., et al., Secondary prevention of macrovascular events in patients with type 2 ­diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet, 2005. 366(9493): p. 1279–89.PubMedGoogle Scholar
  316. Piccinni et al., Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care, 2011. (34): p. 1369–71.Google Scholar
  317. Okumura, T., Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs. J Gastroenterol, 2010.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Division of Endocrinology, Diabetes and Bone Diseases, The Samuel Bronfman Department of MedicineMount Sinai School of MedicineNew YorkUSA

Personalised recommendations